BR112016008267A2 - Composição para prevenir ou tratar esclerose lateral amiotrófica usando duas ou mais isoformas de fator de crescimento de hepatócito - Google Patents

Composição para prevenir ou tratar esclerose lateral amiotrófica usando duas ou mais isoformas de fator de crescimento de hepatócito

Info

Publication number
BR112016008267A2
BR112016008267A2 BR112016008267A BR112016008267A BR112016008267A2 BR 112016008267 A2 BR112016008267 A2 BR 112016008267A2 BR 112016008267 A BR112016008267 A BR 112016008267A BR 112016008267 A BR112016008267 A BR 112016008267A BR 112016008267 A2 BR112016008267 A2 BR 112016008267A2
Authority
BR
Brazil
Prior art keywords
composition
isoforms
lateral sclerosis
amyotrophic lateral
preventing
Prior art date
Application number
BR112016008267A
Other languages
English (en)
Inventor
Gyun Jeong Jae
Original Assignee
Viromed Co Ltd
Helixmith Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viromed Co Ltd, Helixmith Co Ltd filed Critical Viromed Co Ltd
Priority claimed from PCT/KR2014/009971 external-priority patent/WO2015060650A2/ko
Publication of BR112016008267A2 publication Critical patent/BR112016008267A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]

Abstract

COMPOSIÇÃO PARA PREVENIR OU TRATAR ESCLEROSE LATERAL AMIOTRÓFICA USANDO DUAS OU MAIS ISOFORMAS DE FATOR DE CRESCIMENTO DE HEPATÓCITO. A presente invenção refere-se a uma composição para prevenir ou tratar esclerose lateral amiotrófica, a composição contendo, como um princípio ativo, duas ou mais isoformas de um fator de crescimento de hepatócito (HGF) ou um polinucleotídeo que codifica as isoformas. A composição da presente invenção é usada para prevenir ou tratar eficazmente esclerose lateral amiotrófica.
BR112016008267A 2013-10-22 2014-10-22 Composição para prevenir ou tratar esclerose lateral amiotrófica usando duas ou mais isoformas de fator de crescimento de hepatócito BR112016008267A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20130126216 2013-10-22
PCT/KR2014/009971 WO2015060650A2 (ko) 2013-10-22 2014-10-22 간세포 성장인자의 둘 이상의 이형체를 이용한 근위축성 측삭 경화증 예방 또는 치료용 조성물
KR1020140143377A KR101779775B1 (ko) 2013-10-22 2014-10-22 간세포 성장인자의 둘 이상의 이형체를 이용한 근위축성 측삭 경화증 예방 또는 치료용 조성물

Publications (1)

Publication Number Publication Date
BR112016008267A2 true BR112016008267A2 (pt) 2017-10-03

Family

ID=53386224

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016008267A BR112016008267A2 (pt) 2013-10-22 2014-10-22 Composição para prevenir ou tratar esclerose lateral amiotrófica usando duas ou mais isoformas de fator de crescimento de hepatócito

Country Status (13)

Country Link
US (1) US10639351B2 (pt)
EP (1) EP3061457B1 (pt)
JP (1) JP6240337B2 (pt)
KR (2) KR101779775B1 (pt)
CN (1) CN105682676B (pt)
AU (1) AU2014337870B2 (pt)
BR (1) BR112016008267A2 (pt)
CA (1) CA2926607C (pt)
ES (1) ES2773305T3 (pt)
HK (1) HK1219873A1 (pt)
MX (1) MX2016005006A (pt)
RU (1) RU2639582C2 (pt)
SG (1) SG11201602452SA (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3046202B1 (fr) * 2015-12-24 2017-12-29 Snecma Turboreacteur avec un moyen de reprise de poussee sur le carter inter-compresseurs
EP3733855A4 (en) * 2017-12-29 2021-03-03 Helixmith Co., Ltd ADENO-ASSOCIATED VIRUS (AAV) VECTOR INCLUDING A HYBRID HGF GENE INTRODUCED INTO ITS BREAST
EP3823982A4 (en) * 2018-07-17 2022-04-13 Helixmith Co., Ltd TREATMENT OF NEUROPATHY WITH IGF-1-ENCODING DNA CONSTRUCTS AND HGF-ENCODING DNA CONSTRUCTS
CN110577954A (zh) * 2019-10-12 2019-12-17 北京万福来生物技术有限责任公司 突变的肝细胞生长因子基因及其应用

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0255320A3 (en) 1986-07-28 1989-09-06 Genzyme Corporation Production of proteins in myeloma cells
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
NZ232813A (en) 1989-03-10 1992-08-26 Snow Brand Milk Products Co Ltd Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
CA2022752C (en) 1989-08-11 1998-07-07 Naomi Kitamura Hepatic parenchymal cell growth factor, gene encoding the same, process for producing the factor, and transformants producing the factor
US6706694B1 (en) 1990-03-21 2004-03-16 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
DK0539590T3 (da) 1990-07-13 1999-10-11 Snow Brand Milk Products Co Ltd Plasmid indeholdende DNA, som koder for aminosyresekvensen af TCF-II, en transformeret celle og fremstilling af et fysiolog
US5661133B1 (en) 1991-11-12 1999-06-01 Univ Michigan Collateral blood vessel formation in cardiac muscle by injecting a dna sequence encoding an angiogenic protein
US7323297B1 (en) 1992-04-03 2008-01-29 The Regents Of The University Of California Stabilized polynucleotide complexes and methods
JP3680114B2 (ja) 1993-09-17 2005-08-10 敏一 中村 脳神経障害治療剤
US5837676A (en) 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US6498144B1 (en) 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
US5652225A (en) 1994-10-04 1997-07-29 St. Elizabeth's Medical Center Of Boston, Inc. Methods and products for nucleic acid delivery
US6143714A (en) 1994-10-24 2000-11-07 Regeneron Pharmaceuticals, Inc. Methods of using hepatocyte growth factor to promote survival, growth and differentiation of motor neurons
US20030148968A1 (en) 1995-02-28 2003-08-07 Hammond H. Kirk Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
JP3927248B2 (ja) 1995-07-11 2007-06-06 第一製薬株式会社 Ｈｇｆ凍結乾燥製剤
DE69634567T2 (de) 1995-08-29 2006-02-16 Anges Mg Inc., Toyonaka Ein medikament,das hgf gen enthält
US5830879A (en) 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor
US6121246A (en) 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
JP2002515065A (ja) 1997-05-06 2002-05-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 脈管形成トランスジーンのインビボ送達により心不全および心室再構成を処置するための技術および組成物
WO1999036103A1 (en) 1998-01-16 1999-07-22 Mcgill University Prevention and treatment of neuropathy by hepatocyte growth factor
JPH11246433A (ja) 1998-03-03 1999-09-14 Sumitomo Pharmaceut Co Ltd 心筋梗塞治療剤
US20040228834A1 (en) 1998-03-09 2004-11-18 Jeffrey Isner Compositions and methods for modulating vascularization
AU766238B2 (en) 1998-03-09 2003-10-09 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Compositions and methods for modulating vascularization
US7276359B1 (en) 1998-03-13 2007-10-02 Wyeth Polynucleotide composition, method of preparation, and use thereof
DK1061955T3 (da) 1998-03-13 2005-07-04 Wyeth Corp Polynukleotidsammensætning, fremstillingsmetode og anvendelse deraf
AU765177B2 (en) 1998-03-13 2003-09-11 Wyeth Polynucleotide composition, method of preparation, and use thereof
AU5065599A (en) 1998-08-05 2000-02-28 Sumitomo Pharmaceuticals Company, Limited Preparations for the administration of hepatocyte growth factor
KR20000046969A (ko) 1998-12-31 2000-07-25 이선경 이종 유전자 유래의 유전자 발현 조절요소를 포함하는 강력한전사 활성을 가진 진핵세포 발현벡더
CN1182874C (zh) 1999-10-29 2005-01-05 安增子摩祺株式会社 糖尿病性局部缺血疾病的基因治疗制剂
EP1225921A1 (en) 1999-11-05 2002-07-31 The Regents of the University of California TECHNIQUES AND COMPOSITIONS FOR TREATING CARDIOVASCULAR DISEASE BY i IN VIVO /i GENE DELIVERY
DE60134021D1 (de) 2000-06-27 2008-06-26 Anges Mg Inc Pharmazeutische zubereitungen zur angiogenese-therapie
CN1466463A (zh) 2000-09-13 2004-01-07 中外制药株式会社 缺血性疾病治疗剂
US20030176347A1 (en) * 2003-05-14 2003-09-18 Toshikazu Nakamura Remedies for amyotrophic lateral sclerosis
JP5442173B2 (ja) 2000-09-14 2014-03-12 敏一 中村 筋萎縮性側索硬化症治療剤
CN1150035C (zh) 2000-12-21 2004-05-19 中国人民解放军军事医学科学院放射医学研究所 一种重组质粒及其在疾病防治中的应用
US20020172663A1 (en) 2001-01-23 2002-11-21 Maria Palasis Localized myocardial injection method for treating ischemic myocardium
KR100562824B1 (ko) 2002-03-20 2006-03-23 주식회사 바이로메드 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자
US20140170116A9 (en) 2002-08-22 2014-06-19 Marc S. Penn Method of treating ischemic disorders
WO2004060059A2 (en) 2002-12-23 2004-07-22 Vical Incorporated Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes
US20050164208A1 (en) 2004-01-22 2005-07-28 Paul Poulin Storage of genetic information
KR100833612B1 (ko) 2004-12-29 2008-05-30 에프씨비파미셀 주식회사 간엽 간세포로부터 분화된 신경세포를 유효성분으로함유하는 신경계 질환 치료용 약학 조성물
WO2006121532A2 (en) 2005-03-31 2006-11-16 Mytogen, Inc. Treatment for heart disease
US20070212390A1 (en) 2005-09-22 2007-09-13 Ludwig Institute For Cancer Research Protease-resistant forms of VEGF-D, method of making and method of use
CA2628928A1 (en) 2005-11-10 2007-05-24 Receptor Biologix, Inc. Hepatocyte growth factor intron fusion proteins
EP2022853A4 (en) 2006-05-17 2010-03-10 Yoshiyuki Koyama FREEZERED PRODUCT FOR THE TRANSFER OF NUCLEIC ACID, OLIGONUCLEIC ACID OR DERIVATIVES THEREOF
WO2007142651A1 (en) 2006-06-09 2007-12-13 Caritas St. Elizabeth Medical Center Of Boston, Inc. Methods and compositions for the treatment of neuropathy
EP2218459B1 (en) 2007-11-07 2012-02-01 Ono Pharmaceutical Co., Ltd. Sustained release composition containing sdf-1
US20090202606A1 (en) 2008-01-25 2009-08-13 Viromed Co., Ltd. Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor
AU2009234598C1 (en) 2008-04-09 2012-08-23 Viromed Co., Ltd. Lyophilized DNA formulations for enhanced expression of plasmid DNA
RU2413524C1 (ru) * 2009-07-31 2011-03-10 Общество с ограниченной ответственностью "КриоЦентр" Способ лечения психических и неврологических расстройств
WO2011079261A2 (en) 2009-12-23 2011-06-30 Curna, Inc. Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf
WO2012025925A1 (en) 2010-08-24 2012-03-01 Rappaport Family Institute For Research In The Medical Sciences Methods of improving transplantation using sdf-1alpha
WO2013037521A1 (en) 2011-09-16 2013-03-21 Medical Research Council Modified hgf-1k1 polypeptide
WO2013037520A1 (en) 2011-09-16 2013-03-21 Glaxo Group Limited Modified hgf-1k1 polypeptide
JP2013129661A (ja) * 2013-02-20 2013-07-04 Toshiichi Nakamura 筋萎縮性側索硬化症治療剤

Also Published As

Publication number Publication date
JP2016534149A (ja) 2016-11-04
US10639351B2 (en) 2020-05-05
AU2014337870A1 (en) 2016-05-05
CN105682676B (zh) 2020-10-23
KR20170104129A (ko) 2017-09-14
AU2014337870B2 (en) 2019-11-28
RU2016119116A (ru) 2017-11-28
KR101860452B1 (ko) 2018-05-24
SG11201602452SA (en) 2016-05-30
RU2639582C2 (ru) 2017-12-21
JP6240337B2 (ja) 2017-11-29
ES2773305T3 (es) 2020-07-10
EP3061457B1 (en) 2020-01-22
KR101779775B1 (ko) 2017-09-21
HK1219873A1 (zh) 2017-04-21
EP3061457A4 (en) 2017-06-07
KR20150047108A (ko) 2015-05-04
EP3061457A2 (en) 2016-08-31
CN105682676A (zh) 2016-06-15
CA2926607A1 (en) 2015-04-30
CA2926607C (en) 2018-10-23
MX2016005006A (es) 2016-07-14
US20160250291A1 (en) 2016-09-01

Similar Documents

Publication Publication Date Title
BR112017020999A2 (pt) inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer
BR112015021999A2 (pt) inibidores de indoleamina 2,3-dioxigenase (ido)
BR112015032595A2 (pt) inibidores de ido
PH12015502028A1 (en) Ido inhibitors
BR112015022417A2 (pt) métodos e composições para inibição de proteínas contendo bromodomínio
CO7111303A2 (es) Compuestos de microarn y métodos de modulación de la actividad de mir-21
BR112016021648A2 (pt) novos compostos
MX2020001258A (es) Moduladores del factor del complemento b.
MX366875B (es) Inhibidores de indoleamina 2,3-dioxigenasa (ido).
ECSP14017269A (es) Compuestos para tratar la atrofia muscular espinal
PH12016501160A1 (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
PH12016502062A1 (en) Compositions and methods for modulating completent factor b expression
EA201491970A1 (ru) Циклические мостиковые простые эфиры в качестве ингибиторов dgat1
BR112015018360A2 (pt) terapia de combinação para o tratamento de pneumonia nosocomial
BR112016011472A2 (pt) tienopirimidinas como inibidores de mknk1 e mknk2
BR112018073944A2 (pt) uso de uma composição.
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
BR112016008267A2 (pt) Composição para prevenir ou tratar esclerose lateral amiotrófica usando duas ou mais isoformas de fator de crescimento de hepatócito
BR112014010594A2 (pt) terapia genética para neuropatia diabética empregando um isoforma do hgf
BR112018008931A2 (pt) ?compostos para tratamento de distúrbios hipoproliferativos?
BR112016000338A8 (pt) composto enriquecido em deutério de fórmula estrutural i, composição farmacêutica, e usos de um composto
BR112016021656A2 (pt) inibidores das vias de sinalização de wnt
EA201500736A1 (ru) Пиразолилкарбоксамиды i в качестве ингибиторов crac каналов
BR112018077440A2 (pt) uma composição para uso no tratamento de infecção de rotavírus
BR112017008686A2 (pt) uso e método cosmético

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B25D Requested change of name of applicant approved

Owner name: HELIXMITH CO., LTD (KR)

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.